Galmed Pharmaceuticals
GLMD
24 hedge funds and large institutions have $804K invested in Galmed Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
14% more funds holding
Funds holding: 21 → 24 (+3)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
53% less capital invested
Capital invested by funds: $1.7M → $804K (-$896K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$10.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$10.2K |
| 3 |
Renaissance Technologies
New York
|
+$8.88K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$8.88K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$6.83K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$19.1K |
| 2 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$3.41K |
| 3 |
Citigroup
New York
|
-$3K |
| 4 |
Morgan Stanley
New York
|
-$2.73K |
| 5 |
Millennium Management
New York
|
-$1.36K |
GLMD Hedge Fund Activity: Q3 2022 in Review
24 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2022, worth a combined $804K — down 53% from $1.7M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new GLMD positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 6 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $10.9K. The largest seller was Citadel Advisors, cutting an estimated $19.1K.
- 24 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2022, up from 21 in Q2 2022.
- Funds reported $804K of Galmed Pharmaceuticals stock for Q3 2022, down 53% quarter-over-quarter.
- 5 funds opened new Galmed Pharmaceuticals positions in Q3 2022 and 2 closed out, a net change of +3 holders.
- The largest Galmed Pharmaceuticals buyer in Q3 2022 was Virtu Financial, an estimated $10.9K added.
- The largest Galmed Pharmaceuticals seller in Q3 2022 was Citadel Advisors, an estimated $19.1K sold.
Based on aggregated 13F filings for Q3 2022.